Net Clinical Benefit of Prehospital Glycoprotein IIb/IIIa Inhibitors in Patients with ST-Elevation Myocardial Infarction and High Risk of Bleeding: Effect of Tirofiban in Patients at High Risk of Bleeding Using CRUSADE Bleeding Score

Volume 24 - Issue 3 - March 2012
Posted on: 2/29/12
0 Comments
6040 reads

Author(s):

Renicus S. Hermanides, MD¹, Jan Paul Ottervanger, MD, PhD¹, Jurrien M. ten Berg, MD, PhD²,
A.T. Marcel Gosselink, MD, PhD¹, Gert van Houwelingen, MD³, Jan-Henk E. Dambrink, MD, PhD¹,
Pieter R. Stella, MD, PhD⁴, Christian Hamm, MD, PhD⁵, Arnoud W.J. van ’t Hof, MD, PhD¹, on behalf of the On-TIME 2 Trial Investigators

References

Van ’t Hof AWJ, Ten Berg JM, Heestermans AA, et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet. 2008;372(9638):537-546.
Ten Berg JM, van ’t Hof AWJ, Dill T, et al; Ongoing Tirofiban In Myocardial infarction Evaluation (On-TIME) 2 study group. Effect of early, pre-hospital initiation of high-bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short and long-term clinical outcome. J Am Coll Cardiol. 2010;55(22):2446-2455.
Hermanides RS, Ottervanger JP, Dambrink JHE, et al. Risk of bleeding after pre-hospital administration of high dose tirofiban for ST-elevation myocardial infarction. Int J Cardiol. 2010 Dec 29 (Epub ahead of print).
Kinnaird TD, Satbile E, Mintz GS, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol. 2003;92(8):930-935.
Rao SV, O’Grady K, Pieper KS, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol. 2005;96(9):1200-1206.
Eikelboom JW, Metha SR, Anand SS, et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114(8):774-782.
Feit F, Voeltz MD, Attubato MJ, et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 trial. Am J Cardiol. 2007;100(9):1364-1369.
Manoukian SV, Feit F, Mehran R, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY trial. J Am Coll Cardiol. 2007;49(12):1362-1368.
Ndrepepa G, Berger PB, Mehilli J, et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol. 2008;51(7):690-697.
Van ’t Hof AWJ, Hamm C, Rasoul S, et al, on behalf of the On-TIME 2 investigators. Ongoing tirofiban in myocardial infarction evaluation (On-TIME) 2 trial: rationale and study design. EuroIntervention. 2007;3(3):371-380.
Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial — phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988;11(1):1-11.
Cockgroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
Subherwal S, Bach RG, Chen Ay, et al. Baseline risk of major bleeding in non-ST elevation myocardial infarction. Circulation. 2009;119(14):1873-1882.
Goto S, Tamura N, Ishida H. Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions. J Am Coll Cardiol. 2004;44(2):316-323.
Montalescot G, Barragan P, Wittenberg O, et al; the ADMIRAL investigators. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344(25):1895-1903.